Ligand Pharmaceuticals (NASDAQ: LGND) raised its 2026 adjusted earnings-per-share outlook on the back of a strong third quarter, but chose to keep its royalty and total revenue guidance unchanged—a decision that one Wall Street analyst described as conservative.
The biotech royalty company reported third-quarter royalty revenue of $70.3 million, up 51% from the same period a year earlier. That figure came in ahead of both Oppenheimer's estimate of $64.8 million and the broader Wall Street consensus of $63.7 million, according to the investment bank.
Despite that outperformance, Ligand left its full-year royalty and total revenue forecasts where they were. Oppenheimer said the unchanged guidance looks cautious given the stronger royalty run-rate, suggesting the company may be leaving room for upside later.
What is Ligand Pharmaceuticals?
Ligand is a biopharmaceutical company that doesn't sell its own drugs. Instead, it licenses its technology and drug candidates to other companies, earning royalties on their sales. That model means Ligand's revenue is tied to the commercial success of medicines developed by partners.
The company's royalty portfolio includes a wide range of products, and in the third quarter, growth was helped by contributions from XOMA Royalty and specific drugs such as Filspari and Ohtuvayre. Filspari is a treatment for a kidney disease called IgA nephropathy, while Ohtuvayre is an inhaled therapy for chronic obstructive pulmonary disease (COPD).
Royalty revenue is the core of Ligand's business, so a 51% jump is a significant signal that its partnered drugs are selling well. But the company's profitability picture is more nuanced. Adjusted earnings per share rose, but the brief notes that the profit story was "more complicated," suggesting that while revenue grew strongly, costs or other factors may have tempered the bottom-line improvement.
Why the unchanged guidance matters
When a company beats expectations but doesn't raise its outlook, investors often wonder whether management is being overly cautious or whether the beat is not sustainable. In Ligand's case, Oppenheimer's view is that the guidance is conservative—meaning the company could be setting a low bar that it can easily clear later.
For everyday investors, conservative guidance can be a double-edged sword. On one hand, it reduces the risk of a future disappointment if sales slow down. On the other, it may mean the stock won't get the immediate boost that a full guidance raise might have provided.
Ligand's decision to lift only its earnings-per-share outlook while holding revenue steady could reflect confidence in improving margins or lower expenses, even if it doesn't want to commit to higher sales just yet.
What it means for investors
For investors, the key takeaway is that Ligand's core royalty business is growing quickly, and the company is beating analyst expectations. That's a positive sign for the underlying health of its partnered drugs.
However, the unchanged revenue guidance suggests management is taking a wait-and-see approach. That could be because some royalty streams are lumpy or because the company wants to see more evidence before committing to a higher forecast.
Investors should also note that Ligand's profitability is not as straightforward as its revenue growth. Adjusted earnings per share rose, but the "more complicated" profit story means it's worth digging into the full earnings report to understand what's driving the bottom line.
In the broader context, Ligand's performance echoes a theme seen across many companies this earnings season: strong results but cautious outlooks. For instance, AbbVie raised its 2026 outlook and hiked its dividend after a strong quarter, while Colgate-Palmolive beat Q3 and lifted its profit outlook despite high costs. On the other hand, SPS Commerce beat estimates but trimmed its revenue outlook, showing that companies are navigating an uncertain environment.
For Ligand, the next thing to watch will be whether the company eventually raises its revenue guidance as the year progresses, and whether the strong royalty growth continues. If the drugs in its portfolio keep selling well, the conservative stance could turn into positive surprises down the road.
As always, investors should consider their own financial situation and risk tolerance before making any decisions. Ligand's story is one of growth, but also of caution—a combination that can offer both opportunity and uncertainty.
